Psychopharmacology of disruptive behavior disorders

Conduct and Oppositional Defiant Disorders: Epidemiology, Risk Factors, and Treatment

Volumn , Issue , 2003, Pages 319-355

  Bukstein, Oscar G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 57449118046     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9781410607720     Document Type: Chapter

References (211)

1. Abikoff, H., & Gittelman, R, (1985). Hyperactive children treated with stimulants: Is cognitive training a useful adjunct? Archives of General Psychiatry 42, 953-961.
2. Abikoff, H., & Hechtman, L, (1996). Multimodal therapy and stimulants in the treatment of children with ADHD. In P. Jensen, & E. D. Hibbs (Eds.), Psychosocial treatments for child and adolescent disorders: Empirically based approaches (pp. 341-369). Washington, DC: American Psychological Association.
3. Alvir, J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A, (1993). Clozapineinduced agranulocytosis: Incidence and risk factors in the United States. New England Journal of Medicine 329, 62-167.
4. Aman, M. G., Findling, R. L., Derivan, A., & Merriman, U. (1999, October). Risperidone versus placebo for severe conduct disorder in children with mental retardation. Scientific Proceedings of the Annual Meeting of the American Academy of Child and Adolescent Psychiatry and the Canadian Academy of Child Psychiatry, Toronto. 205.
5. American Academy of Child and Adolescent Psychiatry, (1997). Practice parameters for the assessment and treatment of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 85s-121s.
6. American Academy of Child and Adolescent Psychiatry, (2001). Summary of the practice parameter for the use of stimulant medication in the treatment of children, adolescents and adults. Journal of the American Academy of Child and Adolescent Psychiatry 40, 1352-1355.
7. American Psychiatric Association, (1980). Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: Author.
8. Anderson, J. C., Williams, S., McGee, R., & Silva, P. A, (1987). DSM-III disorders in preadolescent children, prevalence in a large sample from the general population. Archives of General Psychiatry 44, 69-76.
9. Arnold, L., Abikoff, H., Cantwell, D., Conners, C., Elliott, G., Greenhill, L., Hechtman, L., Hinshaw, S., Hoza, B., Jensen, P., Kraemer, H., March, J., Newcorn, J., Pelham, W., Richters, J., Schiller, E., Severe, J., Swanson, J., Vereen, D., & Wells, K, (1997). NIMH Collaborative multimodal treatment study of children with ADHD (MTA): Design, methodology, and protocol evolution. Journal of Attention Disorders 2, 141-158.
10. Barkley, R. A, (1977). A review of stimulant drug research with hyperactive children. Journal of Child Psychology and Psychiatry 18, 137-165.
11. Barkley, R. A, (1982). Hyperactive children: A handbook for diagnosis and treatment. New York:Guilford Press.
12. Barkley, R. A, (1990). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment. New York: Guilford Press.
13. Barkley, R. A, (1997). ADHD and the nature of self-control. New York: Guilford.
14. Barkley, R., McMurray, M., Edelbroch, C., & Robbins, K, (1990). Side effects of MPH in children with attention deficit hyperactivity disorder: A systematic placebo-controlled evaluation. Pediatrics 86, 184-192.
15. Barkley, R. A., Murphy, K., & Kwasnik, D, (1996). Psychological adjustment and adaptive impairments in young adults with ADHD. Journal of Attention Disorders 1, 41-54.
16. Barrickman, L., Noyes, R., Kuperman, S., Schumacher, E., & Verda, M, (1991). Treatment of ADHD with fluoxetine: A preliminary trial. Journal of the American Academy of Child and Adolescent Psychiatry 30, 762-767.
17. Barrickman, L., Perry, P. J., Allen, A. J., Kuperman, S., Arndt, S., Herrmann, K. J., & Schumacher, E, (1995). Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 34, 649-657.
18. Berkovitch, M., Pope, E., Phillips, J., & Koren, G, (1995). Pemoline-associated fulminant liver failure:Testing the evidence for causation. Clinical Pharmacology Therapeutics 57, 696-698.
19. Biederman, J., Baldessarini, R. J., Wright, V., Knee, D., & Harmatz, J. S, (1989). A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry 28, 777-784.
20. Biederman, J., Faraone, S. V., Milberger, S., Jetton, J. G., Chen, L., Mick, E., Greene, R. W., & Russell, R. L, (1996). Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up of children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 35, 1193-1204.
21. Biederman, J., Newcorn, J., & Sprich, S, (1991). Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. American Psychiatry 148, 564-577.
22. Biederman, J., Quinn, D., Weiss, M., Wigel, S., Markabi, S., Weidennan, M., Edson, K., Karlsson, G., & Pohlmann, H. (2001, October). Methylphenidate HCL extended release capsules (Ritalin LA):A new once-daily therapy for ADHD. Poster session presented at annual meeting of American Academy of Child and Adolescent Psychiatry, Honolulu, HI.
23. Biederman, J., Thisted, R. A., Greenhill, L. L., & Ryan, N. D, (1995). Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. Journal of Clinical Psychiatry 56, 87-93.
24. Biederman, J., Wilens, T., Mick, E., Spencer, T., & Farone, S. V, (1999). Pharmacotherapy of Attention- deficit hyperactivity disorder reduces risk for substance use disorder. Pediatrics, 104, e20.
25. Bradley, C, (1937). The behavior of children receiving benzedrine. American Journal of Psychiatry 94, 577-585.
26. Briant, R. H, (1978). An introduction to clinical pharmacology. In J. S. Werry (Ed.), Pediatric psychopharmacology: The use of behavior modifying drugs in children (pp. 3-28). New York:Brunner/Mazel.
27. Brown, R. T., Borden, K. A., Wynne, M. E., Spunt, A. L., & Clingerman, S. R, (1987). Compliance with pharmacological and cognitive treatments for attention deficit disorder. Journal of the American Academy of Child and Adolescent Psychiatry 26, 521-526.
28. Buitelaar, J. K, (2000). Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. Journal of Child and Adolescent Psychopharmacology 10, 19-26.
29. Buitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. M, (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry 62, 239-248.
30. Bukstein, O. G., Brent, D. A., & Kaminer, Y, (1989). Comorbidity of substance abuse and other psychiatric disorders in adolescents. American Journal of Psychiatry 146, 1131-1141.
31. Bukstein, O. G., & Kolko, D. J, (1998). Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. Journal of Clinical Child Psychology 27, 340-351.
32. Bussing, R., & Levin, G. M, (1993). Methamphetamine and fluoxetine treatment of a child with attention- deficit hyperactivity disorder and obsessive-compulsive disorder. Journal of Child & Adolescent Psychopharmacology 3, 53-58.
33. Cadoret, R. J., Yates, W. R., Troughton, E., Woodworth, G., & Stewart, M. A, (1995). Geneticenvironmental interaction in the genesis of aggressivity and conduct disorders. Archives of General Psychiatry 52, 916-924.
34. Campbell, M., Adams, P. B., Small, A. M., Kafantaris, V., Silva, R. R., Shell, J., Perry, R., Overall, J. E., Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. A., & Overall, J. E, (1997). Lithium in hospitalized aggressive children with conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry 34, 445-453.
35. Campbell, M., Armenteros, J. L., Malone, R. P., Adams, P. B., Eisenberg, Z. W., & Overall, J. E, (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry 36, 835-843.
36. Campbell, M., Cohen, I. L., & Small, A. M, (1982). Drugs in aggressive behavior. Journal of the American Academy of Child Psychiatry 21, 107-117.
37. Campbell, M., Gonzalez, N. M., Ernst, M., Silva, R. R., & Werry, J. S, (1993). Antipsychotics (neuroleptics). In J. S. Werry & M. G. Aman (Eds.), Practitioner's guide to psychoactive drugs for children and adolescents (pp. 269-296). New York: Plenum.
38. Campbell, M., Gonzalez, N. M., & Silva, R. R, (1992). The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatric Clinics of North America 15, 69-85.
39. Campbell, M., Kafantaris, V., & Cueva, J. E, (1995). An update on the use of lithium carbonate in aggressive children and adolescents with conduct disorder. Psychopharmacology Bulletin 31, 93-102.
40. Campbell, M., Rapoport, J. L., & Simpson, G. M, (1999). Antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 38, 537-545.
41. Campbell, M., Small, A. M., Green, W. H., Jennings, S. J., Perry, R., Bennett, W. G., & Anderson, L, (1984). Behavioral efficacy of haloperidol and lithium carbonate: A comparison of hospitalized aggressive children with conduct disorder. Archives of General Psychiatry 41, 650-656.
42. Carlson, G. A., Rapport, M. D., Kelly, K. L., & Pataki, C. S, (1995). Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: Separate and combined effects on behavior and mood. Journal of Child and Adolescent Psychopharmacology 5, 191-204.
43. Chandler, M. C., Lopez, F. A., & Boellner, S. W. (2001, October). Long-term safety of SLI1381 in children with ADHD. Poster session presented at annual meeting of American Academy of Child and Adolescent Psychiatry, Honolulu, HI.
44. Chappell, P. B., Leckman, J. F., & Riddle, M. A, (1995). The pharmacologic treatment of tic disorders. Child & Adolescent Psychiatric Clinics of North America 4, 197-216.
45. Coccaro, E. F., & Kavoussi, R. J, (1997). Fluoxetine and impulsive aggressive behavior in personality- disordered subjects. Archives of General Psychiatry 54, 1081-1088.
46. Conners, C. K., Cast, C. D., Guiltieri, C. T., Welder, E., Mark, R., Reissue, A., Welder, R. A., Khayrallah, M., & Ascher, J, (1996). Bupropion hydrochloride in attention deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 35, 1314-1321.
47. Conners, C. K., Eisenberg, L., & Barcai, A, (1967). Effect of dextroamphetamine on children:Studies on subjects with learning disabilities and school behavior problems. Archives of General Psychiatry 17, 478-485.
48. Connor, D. F, (1993). Beta blockers for aggression: A review of the pediatric experience. Journal of Child and Adolescent Psychopharmacology 3, 99-114.
49. Connor, D. F., Fletcher, K. E., & Swanson, J, (1999). A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 38, 1551-1559.
50. Connor, D. F., Ozbayrak, K. R., Benjamin, S., Ma, Y., & Fletcher, K. E, (1997). A pilot study of nadolol for overt aggression in developmentally delayed individuals. Journal of the American Academy of Child and Adolescent Psychiatry 36, 826-834.
51. Cornelius, J. R., Bukstein, O. G., Birmaher, B., Salloum, I. M., Lynch, K., Pollack, N. K., Gershon, S., & Clark, D, (2000). Fluoxetine in adolescents with major depression and an alcohol use disorder:An open label trial. Addictive Behaviors 25, 1-6.
52. Cueva, J. E., Overall, J. E., Small, A. M., Armenteros, J. L., Perry, R., & Campbell, M, (1996). Carbamazepine in aggressive children with conduct disorder: A double-blind and placebocontrolled study. Journal of the American Academy of Child and Adolescent Psychiatry 35, 480-490.
53. Davidson, J. T., & Connor, K. M, (1998). Bupropion sustained release: A therapeutic overview. Journal of Clinical Psychiatry 58, 25-31.
54. Daviss, W. B., Bentivoglio, P., Racusin, R., Brown, K. M., Bostic, J. Q., & Wiley, L, (2001). Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. Journal of the American Academy of Child and Adolescent Psychiatry 40, 307-314.
55. Donnelly, M., Zametkin, A. J., Rapoport, J. L., Ismond, D. R., Weingartner, H., Lane, E., Oliver, J., Linnoila, M., & Potter, W. Z, (1986). Treatment of childhood hyperactivity with desipramine:Plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clinical Pharmacology & Therapeutics 39, 72-81.
56. Donovan, S. J., Stewart, J. W., Nunes, E. V., Quitkin, F. M., Parides, M., Daniel, W., Susser, E., & Klein, D. F, (2000). Divalproex treatment for youth with explosive temper and mood liability:A double-blind, placebo-controlled crossover design. American Journal of Psychiatry 157, 818-820.
57. DuPaul, G. J., & Barkley, R. A. (1990). Medication therapy. In R. A. Barkley (Ed.), Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment (pp. 573-612). New York:Guilford.
58. DuPaul, G. J., Rapport, M. D., & Perriello, L. M, (1991). Teacher ratings of academic skills: The development of the Academic Performance Rating Scale. School Psychology Review 20, 284-300.
59. Eisenberg, L., Lachman, R., Molling, P., Lockner, A., Mizelle, J., & Conners, C, (1961). A psychopharmacologic experiment in a training school for delinquent boys: Methods, problems and findings. American Journal of Orthopsychiatry 33, 431-447.
60. Elia, J., Borcherding, B., Rapoport, J., & Keysor, C, (1991). Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true non-responders? Psychiatry Research 36, 141-155.
61. Fenichel, R. R, (1995). Combining methylphenidate and clonidine: The role of post-marketing surveillance. Journal of Child and Adolescent Psychopharmacology 5, 155-156.
62. Findling, R. L., Aman, M., & Derivan, A. (2000). Long-term safety and efficacy of risperidone in children with significant conduct problems and borderline IQ or mental retardation. Scientific Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology, 224.
63. Findling, R. L., Schwartz, M. A., Flannery, D. J., &Manos, M. J, (1996). Venlafaxine in adults with attention- deficit hyperactivity disorder: An open clinical trial. Journal of Clinical Psychiatry 57, 184-189.
64. Firestone, P, (1982). Factors associated with children's adherence to stimulant medication. American Journal of Orthopsychiatry 52, 447-457.
65. Fischer, M., & Newby, R. F, (1991). Assessment of stimulant response in ADHD children using a refined multimethod clinical protocol. Journal of Clinical Child Psychology 20, 232-244.
66. Food and Drug Administration, U.S. Department of Health and Human Services, (1997). Pemoline and hepatic failure. Food and Drug Administration Bulletin, 27, 3.
67. Frazier, J. A., Meyer, M. C., Biederman, J., Wozniak, J., Wilens, T. E., Spencer, T. J., Kim, G. S., & Shapiro, S, (1999). Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. Journal of the American Academy of Child and Adolescent Psychiatry 38, 960-965.
68. Gadow, K. D., Nolan, E. E., Paolicelli, L. M., & Sprafkin, J, (1991). A procedure for assessing the effects of methylphenidate on hyperactive children in public school settings. Journal of Clinical Child Psychology 20, 268-276.
69. Gadow, K. D., Nolan, E. E., Sverd, J., Sprafkin, J., & Paolicelli, L, (1990). Methylphenidate in aggressive- hyperactive boys: I. Effects on peer aggression in public school settings. Journal of the American Academy of Child and Adolescent Psychiatry 29, 710-718.
70. Gadow, K. D., Pomeroy, J. C., & Nolan, E. E, (1992). A procedure for monitoring stimulant medication in hyperactive mentally retarded school children. Journal of Child & Adolescent Psychopharmacology 2, 131-143.
71. Gammon, G. D., & Brown, T. E, (1993). Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. Journal of Child & Adolescent Psychopharmacology 3, 1-10.
72. Garfinkel, B. D., Wender, P. H., & Sloman, L, (1983). Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. Journal of the American Academy of Child Psychiatry 22, 343-348.
73. Geller, B., Cooper, T. B., Kai, S., Zimmerman, B., Franzier, J., Williams, M., & Heath, J, (1998). Double- blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. Journal of the American Academy of Child and Adolescent Psychiatry 37, 171-178.
74. Ghaziuddin, N., & Alessi, N. E, (1992). An open clinical trial of trazodone in aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry 2, 291-297.
75. Gillberg, C, (2000). Typical neuroleptics in child and adolescent psychiatry. European Child and Adolescent Psychiatry, 9, I/2-I/8.
76. Gillberg, C., Melander, H., von Knorring, A., Janols, L., Thernlund, G., Heggel, B., Edievall-Walin, L., Gustafsson, P., & Kopp, S, (1997). Long-term central stimulant treatment of children with attention-deficit hyperactivity disorder: A randomized double-blind placebo-controlled trial. Archives of General Psychiatry 54, 857-864.
77. Gittelman-Klein, R, (1980). Diagnosis and drug treatment of childhood disorders: Attention deficit disorder with hyperactivity. In D. F. Klein, R. Gittelman-Klein, F. Quitkin, & A. Rifkin (Eds.), Diagnosis and drug treatment of psychiatric disorders, adults and children (pp. 590-695). Baltimore:Williams & Wilkins.
78. Gittelman-Klein, R, (1987). Pharmacotherapy of childhood hyperactivity: An update. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress. New York: Raven.
79. Goldstein, M. G, (1998). Bupropion sustained release and smoking cessation. Journal of Clinical Psychiatry 59, 66-72.
80. Grace, T, (2000). Cellular and molecular neurochemistry of psychostimulant effects on dopamine. In M. Solanto & X. Castellanos (Eds.), The neuropharmacology of psychostimulant drugs:Implications for ADHD (pp. 85-100). New York: Oxford University Press.
81. Green, W. H, (2001). Child and Adolescent Clinical psychopharmacology (3rd ed.). Hagerstown, MD:Lippicott, Williams & Wilkins.
82. Greenhill, L, (1998). Childhood attention deficit hyperactivity disorder, pharmacological treatments. In P. E. Nathan & J. Gorman (Eds.), Treatments that work (pp. 42-64). Philadelphia:Saunders.
83. Greenhill, L. (2001, October). Once-daily methylphenidate treatment for children with ADHD. Poster session presented at annual meeting of American Academy of Child and Adolescent Psychiatry, Honolulu, HI.
84. Greenhill, L., Abikoff, H., Conners, C. K., Elliott, G., Hechtman, L., Hinshaw, S., Hoza, B., Jensen, P., Kraemer, H., March, J., Newcorn, J., Pelham, W., Richters, J., Schiller, E., Severe, J., Swanson, J., Vereen, D., & Wells, K, (1996). Medication treatment strategies in the MTA: Relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry 35, 444-454.
85. Greenhill, L., Pliszka, S., & Dulcan, M. K, (2001). Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry 40, 1352-1355.
86. Greenhill, L. L., Solomon, M., Pleak, R., & Ambrosini, P, (1986). Molindine hydrochloride of hospitalized children with conduct disorder. Journal of Clinical Psychiatry 46, 20-25.
87. Griffith, J. D., Carranza, J., Griffith, C., & Miller, L. I, (1983). Bupropion, clinical assay for amphetamine- like potential. Journal of Clinical Psychiatry 44, 206-208.
88. Grob, C. S., & Coyle, J. T, (1986). Suspected adverse methylphenidate-imipramine interactions in children. Journal of Developmental & Behavioral Pediatrics 7, 265-267.
89. Gualtieri, C. T., & Evans, R. W, (1988). Motor performance in hyperactive children treated with imipramine. Perceptual & Motor Skills 66, 763-769.
90. Gury, C., Canceil, O., & Iaria, P, (2000). Antipsychotic drugs and cardiovascular safety: Current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 26, 62-72.
91. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health.
92. Hedges, D., Reimherr, F. W., Rogers, A., Strong, R., & Wender, P. H, (1995). An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacology Bulletin 31, 779-783.
93. Hinshaw, S. P, (1991). Stimulant medication in the treatment of aggression in children with attentional deficits. Journal of Clinical Child Psychology 12, 301-312.
94. Horrigan, J. P., & Barnhill, L. J, (1995). Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. Journal of Child and Adolescent Psychopharmacology 5, 215-223.
95. Hunt, R. D, (1987). Treatment effects of oral and transdermal clonidine in relationship to methylphenidate:A one pilot study in ADD-H. Psychopharmacology Bulletin 23, 111-114.
96. Hunt, R. D., Arnsten, A. F. T., & Asbell, M. D, (1995). An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 34, 50-54.
97. Hunt, R. D., Capper, S., & O'Connell, P, (1990). Clonidine in child and adolescent psychiatry. Journal of Child and Adolescent Psychopharmacology 1, 87-102.
98. Hunt, R. D., Lau, S., & Ryu, J, (1991). Alternative therapies for ADHD. In L. L. Greenhill & B. B. Osman (Eds.), Ritalin: Theory and patient management (pp. 75-95). New York: Mary Ann Liebert, Inc.
99. Hunt, R. D., Minderaa, R. B., & Cohen, D. J, (1985). Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a doubleblind placebo-crossover therapeutic trial. Journal of the American Academy of Child and Adolescent Psychiatry 24, 617-629.
100. Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., Croghan, I. T., & Sullivan, P. M, (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine 337, 1195-1202.
101. Jacobvitz, D., Srouge, L. A., Stewart, M., & Leffert, N, (1990). Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: A comprehensive review. Journal of the American Academy of Child and Adolescent Psychiatry 29, 677-688.
102. Jaffe, S. L, (1991). Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 30, 773-775.
103. Jensen, P., Kettle, L., Roper, M., Sloan, M., Dulcan, M., Hoven, C., Bird, H., Bauermeister, J., & Payne, J, (1999). Are stimulants overprescribed? Treatment of ADHD in four U.S. Communities. Journal of the American Academy of Child and Adolescent Psychiatry 38, 797-804.
104. Kafantaris, V., Campbell, M., Padron-Gayol, M. V., Small, A. M., Locascio, J. J., & Rosenberg, C. R, (1992). Carbamazepine in hospitalized aggressive conduct disorder children: An open pilot study. Psychopharmacology Bulletin 28, 193-199.
105. Kemph, J. P., DeVane, C. L., Levin, G. M., Jarecke, R., & Miller, R. L, (1993). Treatment of aggressive children with clonidine: Results of an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 32, 577-581.
106. Klein, R. G, (1991). Thioridazine effects on the cognitive performance of children with attentiondeficit hyperactivity disorder. Journal of Child & Adolescent Psychopharmacology 1, 263-270.
107. Klein, R. G., Abikoff, H., Barkley, R. A., Campbell, M., Leckman, J. F., Ryan, N. D., Solanto, M. V., & Whalen, C. K, (1994). Clinical trials in children and adolescents. In R. F. Prien & D. S. Robinson (Eds.), Clinical evaluation of psychotropic drugs: Principles and guidelines (pp. 501-546). New York: Raven.
108. Klein, R., Abikoff, H., Klass, E., Ganales, D., Seese, L., & Pollack, S, (1997). Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Archives of General Psychiatry 54, 1073-1080.
109. Kowatch, R. A., Suppes, T., Gilfillan, S. K., Fuentes, R. M., Grannemann, B. D., & Emslie, G. J, (1995). Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: A clinical case series. Journal of Child & Adolescent Psychopharmacology 5, 241-253.
110. Kranzler, H. R., Amin, H., Modesto-Lowe, V., & Oncken, C, (1999). Pharmacologic treatments for drug and alcohol dependence. Psychiatric Clinics of North America 22, 401-423.
111. Kratochvil, C., Heiligenstein, J. H., Dittmann, R., Spencer, T., Biederman, J., Werncke, J., Newcorn, J., Casat, C., Milton, D., & Michelson, D, (2002). Atomoxetine and methyphenidate treatment in ADHD children: A randomized, open-label trial. Poster session presented at annual meeting of AAACAP, Honolulu, HI.
112. Kumra, S., Jacobsen, L. K., Lenane, M., Karp, B. I., Frazier, J. A., Smith, A. K., Bedwell, J., Lee, P., Malanga, C. G., Hamburger, S., & Rapoport, J. L, (1998). Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 37, 377-385.
113. Kutcher, S, (2000). Practical clinical issues regarding child and adolescent psychopharmacology. Child and Adolescent Psychiatric Clinics of North America 9, 245-260.
114. Lahey, B. B., McBurnett, K., Lober, R., & Hart, E. L, (1995). Psychobiology of conduct disorder. In G. P. Scholevar (Ed.), Conduct disorder in children and adolescents: Assessments and Interventions (pp. 27-44). Washington, DC: American Psychiatric Press.
115. Lang, C., & Remington, D, (1994). Treatment with propranolol of severe self-injurious behavior in a blind, deaf, and retarded adolescent. Journal of the American Academy of Child and Adolescent Psychiatry 33, 265-269.
116. Langer, D. H., Sweeney, K. P., Bartenbach, D. E., Davis, P. M., & Menander, K. B, (1986). Evidence of lack of abuse or dependence following pemoline treatment: Results of a retrospective survey. Drug and Alcohol Dependence 17, 213-227.
117. Loeber, R., Burke, J. D., Lahey, B. B., Winters, A., & Zera, M, (2000). Oppositional defiant and conduct disorder: A review of the past 10 years: Part I. Journal of the American Academy of Child Psychiatry 39, 1468-1484.
118. Loeber, R., & Farrington, D. P. (Eds.), (1998). Serious and violent juvenile offenders: Risk factors and successful interventions. Thousand Oaks, CA: Sage.
119. Loeber, R., Farrington, D. P., & Waschbusch, D. A, (1998). Serious and violent juvenile offenders. In R. Loeber & D. P. Farrington (Eds.), Serious and violent juvenile offenders: Risk factors and successful interventions (pp. 13-29). Thousand Oaks, CA: Sage.
120. Loeber, R., & Stouthamer-Loeber, M, (1998). Development of juvenile aggression and violence:Some common misconceptions and controversies. American Psychologist 53, 242-259.
121. Lombroso, P. J., Scahill, L., King, R. A., Lynch, K. A., Cappell, P. B., Peterson, B. S., McDougle, C. J., & Leckman, J. F, (1995). Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report. Journal of the American Academy of Child and Adolescent Psychiatry 34, 1147-1152.
122. Loney, J., & Milich, R, (1982). Hyperactivity, inattention, and aggression in clinical practice. Advances in Developmental and Behavioral Pediatrics 3, 113-147.
123. Lyons, M. J., True, W. R., Eisen, S. A., Goldberg, J., Meyer, J. M., Farone, S. V., Eaves, L. J., & Tsuang, M. T, (1995). Differential heriditability of adult and juvenile trait. Archives of General Psychiatry 52, 906-915.
124. Malone, R. P., & Simpson, G. M, (1998). Use of placebos in clinical trials involving children and adolescents. Psychiatric Service 49, 1413-1414.
125. Maoz, G., Stein, D., Meged, S., Kurzman, L., Levine, J., Valevski, A., Aviv, A., Sirota, P., Kraus, R., Weizman, A., & Berger, B. D, (2000). The antiaggressive action of combined haloperidolpropranolol treatment in schizophrenia. European Psychologist 5, 312-325.
126. Marriage, K., Fine, S., Moretti, M., & Haley, G, (1986). Relationship between depression and conduct disorder in children and adolescents. Journal of the American Academy of Child Psychiatry 25, 687-691.
127. Matochik, J., Nordahl, T., Gross, M., Semple, M., King, A., Cohen, R., & Zametkin, A, (1993). Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology 8, 377-386.
128. McMaster University Evidence-Based Practice Center. (1998). The treatment of attention-deficit/hyperactivity disorder: An evidence report (Contract 290-97-0017). Washington, DC: Agency for Health Care Policy and Research.
129. Miczek, K. A., & Winslow, J. T, (1987). Psychopharmacological research on aggressive behavior. In A. J. Greenshaw & C. T. Dourish (Eds.), Experimental psychopharmacology: Contemporary neuroscience (pp. 27-114). Clifton, NJ: Humana Press.
130. Molina, B., Pelham, W. E., & Roth, J. (1999, June). Stimulant medication and substance use by adolescents with a childhood history of ADHD. Poster session presented at the biennial meeting of the International Society for Research on Child and Adolescent Psychopathology, Barcelona, Spain.
131. MTA Cooperative Group, (1999a). 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Archives of General Psychiatry 56, 1073-1086.
132. MTA Cooperative Group, (1999b). Moderators and mediators of treatment response for children with ADHD: The MTA Study. Archives of General Psychiatry 56, 1088-1096.
133. Murphy, D. A., Pelham, W. E., & Lang, A. R. (1986, August). Methylphenidate effects on aggressiveness in ADD and ADD/CD children. Paper presented at the annual meeting of the American Psychological Association, Washington, DC.
134. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 835-843.
135. Newcorn, J. H., & Halperin, J. M, (1994). Comorbidity among disruptive behavior disorders: Impact on severity, impairment, and response to treatment. Child and Adolescent Psychiatry Clinics of North America 3, 227-252.
136. Offord, D. R., Boyle, M. H., & Racine, Y, (1989). Ontario Child Health Study: Correlates of disorder. Journal of the American Academy of Child Psychiatry 28, 856-860.
137. Pappadopulos, E., & MacIntyre, J. (2001, June). Developing best practice medication guidelines for child and adolescent psychiatric inpatients. New York State Office of Mental Health: Best Practices Conference, New York.
138. Pataki, C. S., Carlson, G. A., Kelly, K. L., Rapport, M. D., & Biancaniello, T. M, (1993). Side effects of methylphenidate and desipramine alone and in combination in children. Journal of the American Academy of Child and Adolescent Psychiatry 32, 1065-1072.
139. Pelco, L. E., Kissel, R. C., Parrish, J. M., & Miltenberger, R. G, (1987). Behavioral management of oral medication administration difficulties among children: A review of literature with case illustrations. Developmental and Behavioral Pediatrics 8, 90-96.
140. Pelham, W. E, (1985). The effects of stimulant drugs on learning and achievement in hyperactive and learning disabled children. In J. K. Torgesen & B. Wong (Eds.), Psychological and educational perspectives on learning disabilities (pp. 259-295). New York: Academic.
141. Pelham, W. E., & Hoza, J, (1987). Behavioral assessment of psychostimulant effects on ADD children in a summer day treatment program. Advances in Behavioral Assessment of Children and Families 3, 3-34.
142. Pelham, W. E., Swanson, J., Furman, M., & Schwindt, H, (1995). Pemoline effects of Children with ADHD: A time-response by dose-response analysis on classroom measures. Journal of the American Academy of Child and Adolescent Psychiatry 34, 1504-1513.
143. Pliska, S. R., McCracken, J. T., & Maas, J. W, (1996). Catecholamines in attention-deficit hyperactivity disorder: Current perspectives. Journal of the American Academy of Child and Adolescent Psychiatry 35, 264-272.
144. Popper, C. W, (1995). Combining methylphenidate and clonidine: Pharmacologic questions and news reports about sudden death. Journal of Child & Adolescent Psychopharmacology 5, 157-166.
145. Popper, C. W, (2000). Pharmacologic alternatives to psychostimulants for the treatment of attention- deficit/hyperactivity disorder. Child and Adolescent Psychiatric Clinics of North America 9, 605-646.
146. Popper, C. W., & Zimnitzky, B, (1995). Sudden death putatively related to desipramine treatment in youth: A fifth case and a review of speculative mechanisms. Journal of Child and Adolescent Psychopharmacology 5, 283-300.
147. Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J, (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology 19, 37-44.
148. Poyurovsky, M., Halperin, E., Enoch, D., Schneidman, M., & Weizman, A, (1995). Fluvoxamine treatment of compulsivity, impulsivity, and aggression. American Journal of Psychiatry 152, 1688-1689.
149. Quinn, P. O., & Rapoport, J. L, (1975). One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. American Journal of Psychiatry 132, 241-245.
150. Rabinowitz, J., Avnon, M., & Rosenberg, V, (1996). Effect of clozapine on physical and verbal aggression. Schizophrenia Research 22, 249-255.
151. Raine, A, (1993). The psychopathology of crime, criminal behavior as a clinical disorder. San Diego, CA: Academic.
152. Raine, A., Venables, P. H., & Williams, M, (1995). High autonomic arousal and electrodermal orienting at age 15 years as protective factors against criminal behavior at age 29 years. American Journal of Psychiatry 152, 1595-1600.
153. Rapoport, J. L., Quinn, P. O., Bradbard, G., Riddle, K. D., & Brooks, E, (1974). Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison. Archives of General Psychiatry 30, 789-793.
154. Rapport, M, (1995). Attention-deficit hyperactivity disorder. In M. Hersen & R. T. Ammerman (Eds.), Advanced abnormal child psychology (pp. 353-373). Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.
155. Rapport, M., Carlson, G., Kelly, K., & Pataki, C, (1993). Methylphenidate and desipramine in hospitalized children. I. Separate and combined effects on cognitive function. Journal of the American Academy of Child and Adolescent Psychiatry 32, 333-342.
156. Rapport, M. D., DuPaul, G. J., Stoner, G., & Jones, J. T, (1986). Comparing classroom and clinic measures of attention deficit disorder: Differential, idiosyncratic, and dose-response effects of methylphenidate. Journal of Consulting and Clinical Psychology 54, 334-341.
157. Remschmidt, H., Hennighausen, K., Clement, H. W., Heiser, P., & Schulz, E. (2000). Atypical neuroleptics in child and adolescent psychiatry. European Child and Adolescent Psychiatry, 9(suppl 1), I/1-I/19.
158. Richardson, M. A., Haugland, G., & Craig, T. J, (1991). Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. American Journal of Psychiatry 148, 1322-1328.
159. Richters, J. E., Arnold, L. E., Jensen, P. S., Abikoff, H., Conners, C. K., Greenhill, L. L., Hechtman, L., Hinshaw, S. P., Pelham, W. E., & Swanson, J. M, (1995). NIMH Collaborative Multisite Multimodal Treatment Study of Children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry 34, 987-1000.
160. Riddle, M. A., Geller, B., & Ryan, N, (1993). Another sudden death treated with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry 32, 792-797.
161. Riddle, M. A., Hardin, M. T., Soo, C. C., Woolston, J. L., et al, (1988). Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: Preliminary clinical experience. Journal of the American Academy of Child and Adolescent Psychiatry 27, 811-814.
162. Riddle, M. A., Kastelic, E. A., & Frosch, E, (2001). Pediatric psychopharmacology. Journal of Child Psychology & Psychiatry & Allied Disciplines 42, 73-90.
163. Riddle, M. A., Nelson, J. C., Kleinman, C. S., Rasmusson, A., et al, (1991). Sudden death in children receiving Norpramin(R): A review of three reported cases and commentary. Journal of the American Academy of Child and Adolescent Psychiatry 30, 104-108.
164. Riggs, P. D, (1998). Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry 37, 331-332.
165. Riggs, P. D., Mikulich, S. K., Coffman, L. M., & Crowley, T. J, (1997). Fluoxetine in drug-dependent delinquents with major depression: An open trial. Journal of Child and Adolescent Psychopharmacology 7, 87-95.
166. Riggs, P. D., Thompson, L. L., Mikulich, S. K., Whitmore, E. A., & Crowley, T. J, (1996). An open trial of pemoline in drug dependent delinquents with attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 35, 1018-1024.
167. Ryan, N. D, (1992). The pharmacologic treatment of child and adolescent depression. Psychiatric Clinics of North America 15, 29-40.
168. Safer, D. J., Zito, J. M., & Gardner, J. F, (2001). Pemoline hepatotoxicity and postmarketing surveillance. Journal of the American Academy of Child Psychiatry 40, 622-629.
169. Sallee, F., Stiller, R., & Perel, J, (1992). Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry 31, 244-251.
170. Sallee, F. R., Stiller, R. L., & Perel, M. M., et al, (1989). Pemoline-induced abnormal involuntary movements. Journal of Clinical Psychopharmacology 9, 125-129.
171. Sallee, F. R., Stiller, R., Perel, J., & Bates, T, (1985). Oral pemoline kinetics in hyperactive children. Clinical Pharmacological Therapy 37, 606-609.
172. Saul, R. C, (1985). Nortriptyline in attention deficit disorder. Clinical Neuropharmacology 8, 382-384.
173. Schachar, R., & Tannock, R, (1993). Childhood hyperactivity and psychostimulants: A review of extended treatment studies. Journal of Child and Adolescent Psychopharmacology 3, 81-97.
174. Schachar, R., Tannock, R., Cunningham, C., & Corkum, P, (1997). Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry 36, 754-763.
175. Schmidt, K., Solanto, M. V., & Sanchez, M, (1984). The effect of stimulant medication of academic performance, in the context of multimodal treatment, in attention deficit disorders with hyperactivity. Journal of Clinical Psychopharmacology 4, 100-103.
176. Schreier, H. A, (1998). Risperidone for young children with mood disorders and aggressive behavior. Journal of Child & Adolescent Psychopharmacology 8, 49-59.
177. Settle, E. C, (1998). Bupropion sustained release, side effect profile. Journal of Clinical Psychiatry 59, 32-36.
178. Sikich, L. (2001, May). Comparative use of olanzapine and risperidone in psychotic youth. 154th Annual Meeting of the American Psychiatric Association, 326.
179. Silva, R. R., Campbell, M., Golden, R. R., Small, A. M., Pataki, C. S., & Rosenberg, C. R, (1992). Side effects associated with lithium and placebo administration in aggressive children. Psychopharmacological Bulletin 28, 319-326.
180. Simeon, J. G., Ferguson, H. B., & Fleet, J. V. W, (1986). Bupropion effects in attention deficit and conduct disorders. Canadian Journal of Psychiatry 31, 581-585.
181. Smith, B. H., Pelham, W. E., Gnagy, E., & Yudell, R. S, (1998). Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence. Journal of the American Academy of Child and Adolescent Psychiatry 37, 314-321.
182. Solhkhah, R., & Wilens, T. E, (1998). Pharmacotherapy of adolescent AOD use disorders. Alcohol Health & Research World 22, 122-126.
183. Spencer, T., Biederman, J., Harding, M., Faraone, S., & Wilens, T, (1996). Growth deficits in ADHD children revisited: Evidence for disorder related growth delays. Journal of the American Academy of Child and Adolescent Psychiatry 35, 1460-1467.
184. Spencer, T., Biederman, J., Wilens, T., Harding, M., O'Donnell, D., & Griffin, S, (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry 35, 409-432.
185. Spencer, T., Biederman, J., Kerman, K., Steingard, R., et al, (1993). Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 32, 354-360.
186. Spencer, T., Biederman, J., Wilens, T., Steingard, R., et al, (1993). Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry 32, 205-210.
187. Steingard, R., Biederman, J., Spencer, T., Wilens, T., & Gonzalez, A, (1993). Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. Journal of the American Academy of Child and Adolescent Psychiatry 32, 350-353.
188. Stoner, G., Carey, S. P., Ikeda, M. J., & Shinn, M. R, (1994). The utility of curriculum-based measurement for evaluating the effects of methylphenidate on academic performance. Journal of Applied Behavioral Analysis 27, 101-113.
189. Swanson, J, (1993). Effect of stimulant medication on hyperactive children: A review of reviews. Exceptional Child 60, 154-162.
190. Swanson, J., Lerner, M., & Williams, L, (1995). More frequent diagnosis of attention deficithyperactivity disorder. New England Journal of Medicine 333, 944-944.
191. Swanson, J., & Volkow, N, (2000). Pharmacodynamics and pharmacokinetics of stimulants in AD/HD. In M. Solanto & X. Castellanos (Eds.), The neuropharmacology of psychostimulant drugs:Implications for AD/HD (pp. 101-125). New York: Oxford University Press.
192. Szatmari, P., Offord, D. R., & Boyle, M. H, (1989). Ontario Child Health Study: Prevalence of attention deficit disorder with hyperactivity. Journal of Child Psychology and Psychiatry 30, 219-230.
193. Thurber, S., & Walker, C, (1983). Medication and hyperactivity: A meta-analysis. Journal of General Psychiatry 108, 79-86.
194. Varley, C. K., & McClellan, J, (1997). Case study: Two additional sudden deaths with tricyclic antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry 36, 390-394.
195. Vitiello, B., Behar, D., Hunt, J., Stoff, D., & Ricciuti, A. J, (1990). Subtyping aggression in children and adolescents. Journal of Neuropsychiatry and Clinical Neurosciences 2, 189-192.
196. Vitiello, B., Ricciuti, A. J., & Behar, D, (1987). P.R.N. medications in child state hospital inpatients. Journal of Clinical Psychiatry 48, 351-354.
197. Volkow, N., Wang, G., Fowler, J., Gatley, S., Logan, J., Ding, Y., Hitzemann, R., & Pappas, N, (1998). Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry 155, 1325-1331.
198. Waizer, J., Hoffman, S. P., Polizos, P., & Engelhardt, D. M, (1974). Outpatient treatment of hyperactive school children with imipramine. American Journal of Psychiatry 131, 587-591.
199. Walkup, J. T, (1995). Clinical decision making in child and adolescent psychopharmacology. Child & Adolescent Psychiatric Clinics of North America 4, 23-40.
200. Weiss, G., & Hechtman, L. T, (1993). Hyperactive children grown up: ADHD in children, adolescents, and adults (2nd ed.). New York: Guilford Press.
201. Werry, J. S., Aman, M. G., & Diamond, E, (1980). Imipramine and methylphenidate in hyperactive children. Journal of Child Psychology & Psychiatry & Allied Disciplines 21, 27-35.
202. Whalen, C. K., & Henker, B, (1991). Social impact of stimulant treatment for hyperactive children. Journal of Learning Disabilities 24, 231-241.
203. Whitaker, A., & Rao, U, (1992). Neuroleptics in pediatric psychiatry. Psychiatric Clinics of North America 15, 243-277.
204. Wilens, T. E., Biederman, J., Baldessarini, R. J., Geller, B., et al, (1996). Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 35, 1491-1501.
205. Wilens, T. E., Biederman, J., Geist, D. E., Steingard, R., et al, (1993). Nortriptyline in the treatment of ADHD: A chart review of 58 cases. Journal of the American Academy of Child and Adolescent Psychiatry 32, 343-349.
206. Wilens, T. E., Biederman, J., & Spencer, T. J, (1994). Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 33, 424-426.
207. Wilens, T. E., Spencer, T. J., & Biederman, J, (1997). Sudden (un)explained death. Journal of the American Academy of Child and Adolescent Psychiatry 36, 1487-1488.
208. Zametkin, A. et al, (1985). Treatment of hyperactive children with monoamine oxidase inhibitors:I. Clinical efficacy. Archives of General Psychiatry 42, 962-966.
209. Zametkin, A. J., Nordahl, T. E., Gross, M., King, A. C., Semple, W. E., Rumsey, J., Hamburger, S., & Cohen, R. M, (1990). Cerebral glucose metabolism in adults with hyperactivity of childhood onset. New England Journal of Medicine 323, 1361-1366.
210. Zito, J. M., Safer, D. J., dosReis, S., Gardner, J. F., Boles, M., & Lynch, F, (2000). Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association 283, 1025-1030.
211. Zito, J. M., Safer, D. J., Riddle, M. A., Johnson, R. E., Speedie, S. M., & Fox, M, (1998). Prevalence variations in psychotropic treatment of children. Journal of Child & Adolescent Psychopharmacology 8, 99-105.